These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25865580)

  • 1. Who is too healthy and who is too sick for liver transplantation: external validation of prognostic scores and survival-benefit estimation.
    Åberg F; Nordin A; Mäkisalo H; Isoniemi H
    Scand J Gastroenterol; 2015; 50(9):1144-51. PubMed ID: 25865580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing repeat liver transplant graft utility through strategic matching of donor and recipient characteristics.
    Hung K; Gralla J; Dodge JL; Bambha KM; Dirchwolf M; Rosen HR; Biggins SW
    Liver Transpl; 2015 Nov; 21(11):1365-73. PubMed ID: 25865434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should a lower quality organ go to the least sick patient? Model for end-stage liver disease score and donor risk index as predictors of early allograft dysfunction.
    Croome KP; Marotta P; Wall WJ; Dale C; Levstik MA; Chandok N; Hernandez-Alejandro R
    Transplant Proc; 2012 Jun; 44(5):1303-6. PubMed ID: 22664005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: results from a multicenter Spanish study.
    Briceño J; Cruz-Ramírez M; Prieto M; Navasa M; Ortiz de Urbina J; Orti R; Gómez-Bravo MÁ; Otero A; Varo E; Tomé S; Clemente G; Bañares R; Bárcena R; Cuervas-Mons V; Solórzano G; Vinaixa C; Rubín A; Colmenero J; Valdivieso A; Ciria R; Hervás-Martínez C; de la Mata M
    J Hepatol; 2014 Nov; 61(5):1020-8. PubMed ID: 24905493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes.
    Trotter JF; Osgood MJ
    JAMA; 2004 Apr; 291(15):1871-4. PubMed ID: 15100206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model for end-stage liver disease-sodium and survival benefit in liver transplantation.
    Vitale A; Bertacco A; Gambato M; D'Amico F; Morales RR; Frigo AC; Zanus G; Burra P; Angeli P; Cillo U
    Transpl Int; 2013 Feb; 26(2):138-44. PubMed ID: 23194386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-Model for End-Stage Liver Disease and donor-recipient matching in liver transplantation.
    Vitale A; Ramirez Morales R; dalla Bona E; Scopelliti M; Zanus G; Neri D; d'Amico F; Gringeri E; Russo F; Burra P; Angeli P; Cillo U
    Transplant Proc; 2011 May; 43(4):974-6. PubMed ID: 21620029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival benefit after liver transplantation: a single European center experience.
    Ravaioli M; Grazi GL; Dazzi A; Bertuzzo V; Ercolani G; Cescon M; Cucchetti A; Masetti M; Ramacciato G; Pinna AD
    Transplantation; 2009 Sep; 88(6):826-34. PubMed ID: 19920783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
    Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
    Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the MELD allocation after its implementation in liver transplantation.
    Benckert C; Quante M; Thelen A; Bartels M; Laudi S; Berg T; Kaisers U; Jonas S
    Scand J Gastroenterol; 2011 Jul; 46(7-8):941-8. PubMed ID: 21443420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low, rather than high, body mass index confers increased risk for post-liver transplant death and graft loss: Risk modulated by model for end-stage liver disease.
    Bambha KM; Dodge JL; Gralla J; Sprague D; Biggins SW
    Liver Transpl; 2015 Oct; 21(10):1286-94. PubMed ID: 26097202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes in liver transplant recipients with Model for End-stage Liver Disease scores of 40 or higher: a decade-long experience.
    Panchal HJ; Durinka JB; Patterson J; Karipineni F; Ashburn S; Siskind E; Ortiz J
    HPB (Oxford); 2015 Dec; 17(12):1074-84. PubMed ID: 26373873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of postoperative Model for End-Stage Liver Disease scoring system for evaluating liver graft function after living donor liver transplantation.
    Toshima T; Ikegami T; Kimura K; Harimoto N; Yamashita Y; Yoshizumi T; Soejima Y; Ikeda T; Shirabe K; Maehara Y
    Transplant Proc; 2014; 46(1):81-6. PubMed ID: 24507030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live donor liver transplantation in high MELD score recipients.
    Selzner M; Kashfi A; Cattral MS; Selzner N; McGilvray ID; Greig PD; Levy GA; Renner EL; Grant DR
    Ann Surg; 2010 Jan; 251(1):153-7. PubMed ID: 19858705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs.
    Foxton MR; Al-Freah MA; Portal AJ; Sizer E; Bernal W; Auzinger G; Rela M; Wendon JA; Heaton ND; O'Grady JG; Heneghan MA
    Liver Transpl; 2010 May; 16(5):668-77. PubMed ID: 20440776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waiting time, not donor-risk-index, is a major determinant for beneficial outcome after liver transplantation in high-MELD patients.
    Rauchfuss F; Zidan A; Scheuerlein H; Dittmar Y; Bauschke A; Settmacher U
    Ann Transplant; 2013 May; 18():243-7. PubMed ID: 23792527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era.
    Lee WC; Chan KM; Chou HS; Wu TJ; Lee CF; Soong RS; Wu TH; Lee CS
    Ann Surg; 2013 Aug; 258(2):306-11. PubMed ID: 23108123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of MELD and Child-Turcotte-Pugh scores and the Canadian waitlisting algorithm in predicting short-term survival after liver transplant.
    Bazarah SM; Peltekian KM; McAlister VC; Bitter-Suermann H; MacDonald AS
    Clin Invest Med; 2004 Aug; 27(4):162-7. PubMed ID: 15453152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis.
    Dutkowski P; Oberkofler CE; Béchir M; Müllhaupt B; Geier A; Raptis DA; Clavien PA
    Liver Transpl; 2011 Jun; 17(6):674-84. PubMed ID: 21618688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.